Cargando…

523. Use of Immune-Viral Dynamics Modeling to Understand Molnupiravir Drug Effect for COVID-19

BACKGROUND: Molnupiravir (MOV) is an orally administered ribonucleoside prodrug of β-D-N4-hydroxycytidine (NHC) against SARS-CoV-2. Here we present viral dynamics analysis of Phase 2 clinical virology data to inform MOV Phase 3 study design and development strategy. METHODS: An Immune-Viral Dynamics...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Youfang, Gao, Wei, Birger, Ruthie, Stone, Julie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644542/ http://dx.doi.org/10.1093/ofid/ofab466.722

Ejemplares similares

Immune‐viral dynamics modeling for SARS‐CoV‐2 drug development
por: Cao, Youfang, et al.
Publicado: (2021)

543. Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies
por: Grobler, Jay, et al.
Publicado: (2021)

523. COVID-19 Preparedness in Hospice and Palliative Care
por: Pogorzelska-Maziarz, Monika, et al.
Publicado: (2020)

PM523. Psychopharmacology and Psychosocial Rehabilitation to Achieve Recovery in Indonesia
por: Kembaren, Lahargo
Publicado: (2016)

523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
por: Lee, Kiriam Escobar, et al.
Publicado: (2023)

511. Treatment with Molnupiravir in the MOVe-In and MOVe-Out Clinical Trials Results in an Increase in Transition Mutations Across the SARS-CoV-2 Genome
por: Strizki, Julie, et al.
Publicado: (2021)

523. Dual vs. Triple Antibiotic Therapy for Carbapenem-Resistant Acinetobacter baumannii Infections
por: Markelwith, Justin Patrick, et al.
Publicado: (2019)

523. Use of Whole-Genome Sequencing to Guide a C. difficile Diagnostic Stewardship Program
por: Jakharia, Kunal, et al.
Publicado: (2018)

A Study of 523 Cases of Obesity
por: Dunlop, D. M., et al.
Publicado: (1931)

153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro
por: Strizki, Julie, et al.
Publicado: (2022)

523. A Rapid, Objective Measure of the Host Response May Help Guide Efficient and Judicious ED Care for Sepsis
por: O’Neal, Hollis R, et al.
Publicado: (2022)

P247 and P523: Two In Vivo-Expressed Megalocytivirus Proteins That Induce Protective Immunity and Are Essential to Viral Infection
por: Zhang, Jian, et al.
Publicado: (2015)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

P37 A retrospective audit of molnupiravir prescribing in the virtual hospital via the CMDU pathway
por: Ogunmodede, Christiana, et al.
Publicado: (2023)

547. Molnupiravir and Nirmatrelvir/Ritonavir Effectiveness in Reducing the Risk for COVID-19 Disease Progression and Death
por: Paraskevis, Dimitrios, et al.
Publicado: (2023)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

525. Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
por: Fujita, Kohei, et al.
Publicado: (2023)

514. Nirmatrelvir/ritonavir or Molnupiravir for Treatment of Non-hospitalized Patients with COVID-19 at Risk of Disease Progression
por: Butt, Adeel A, et al.
Publicado: (2023)

P523: THE COMPARISON OF VFLAI, FLAI AND 3 + 7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD
por: Piciocchi, Alfonso, et al.
Publicado: (2023)

Characteristic of 523 COVID-19 in Henan Province and a Death Prediction Model
por: Ma, Xiaoxu, et al.
Publicado: (2020)

P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY
por: Spiliopoulou, V., et al.
Publicado: (2023)

523 Not All Who Wheeze Have Asthma—Tracheal Diverticulum with Stenosis of Trachea in 9 Years Old Boy
por: Kopriva, Frantisek
Publicado: (2012)

Review on molnupiravir as a promising oral drug for the treatment of COVID-19
por: Zarenezhad, Elham, et al.
Publicado: (2022)

523 Reduced Incidence of Fractures After Treatment with Oxandrolone in Burn Patients
por: Walters, Elliot, et al.
Publicado: (2022)

Recovery and sequelae in 523 adults and children with tick-borne encephalitis in Germany
por: Nygren, Teresa M., et al.
Publicado: (2023)

528. Matched Retrospective Study, Comparing Molnupiravir to Nirmatrelvir-Ritonavir (Paxlovid) in the Treatment of Mild-Moderate COVID-19 in Immunocompromised Cancer Patients
por: Haddad, Andrea, et al.
Publicado: (2023)

543. SARS-CoV-2 Viral Dynamics For Symptomatic People Living with HIV Requiring Hospitalization For COVID-19
por: Virata, Michael D, et al.
Publicado: (2020)

Publisher Correction: Molnupiravir: coding for catastrophe
por: Malone, Brandon, et al.
Publicado: (2021)

Molnupiravir, une affaire franco-européenne
por: Manus, Jean-Marie
Publicado: (2021)

Molnupiravir: From Hope to Epic Fail?
por: Focosi, Daniele
Publicado: (2022)

Why Molnupiravir Fails in Hospitalized Patients
por: Brown, Ashley N., et al.
Publicado: (2022)

Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses
por: Wang, Yining, et al.
Publicado: (2021)

P1514: MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY
por: Salmanton-García, Jon, et al.
Publicado: (2023)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

Two New Chroman Derivations from the Endophytic Penicillium sp. DCS523
por: Li, Jun-Tian, et al.
Publicado: (2011)

MON-523 Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

SUN-523 XLH Outcome Data from One Centre Experience with Burosumab
por: Cheung, Moira, et al.
Publicado: (2019)

Genotype-phenotype analysis of 523 patients by genetics evaluation and clinical exome sequencing
por: Ziats, Mark N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8llkq68h4fmjknl0j5hq9ainma